Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease

J JOHN MANN, MICHAEL STANLEY,* RICHARD D KAPLAN, JOHN SWEENEY, ANDREAS NEOPHYTIDES

From the Department of Psychiatry, Payne Whitney Clinic, Cornell University Medical College, New York, USA

SUMMARY Cerebrospinal fluid levels of homovanillic acid (HVA) in unmedicated patients with Parkinson's disease were 45% of levels in control subjects. Levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and platelet monoamine oxidase activity (MAO) did not differ. Within the Parkinson's disease group platelet MAO B activity correlated with HVA (an MAO B substrate) but not MHPG (an MAO A substrate). A mild global dementia was found that did not correlate with the more severe motor deficit. There was a negative correlation between the motor deficit and HVA levels but not with MHPG. Cognitive functioning correlated positively with platelet MAO, and the ratio of HVA to MHPG levels and negatively with MHPG alone. It is postulated that dopaminergic and noradrenergic activity or the functional balance between these systems may contribute to the observed cognitive dysfunction.

Studies of necropsy brain tissue and cerebrospinal fluid have demonstrated a relationship between the motor deficit in Parkinson's disease and levels of dopamine (DA) and homovanillic acid (HVA). In contrast CSF levels of 5-hydroxyindolacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) have not been found to be altered in Parkinson's disease. However, levels of brain norepinephrine (NE) and MHPG are reported as low in certain brain regions postmortem. Other neurochemical findings reported in Parkinson's disease include: decreased activity of dopa decarboxylase in the striatum, alterations in striatal neuroleptic binding and cortical serotonin binding, and reduced methionine-enkephalin levels in the substantia nigra and the ventral tegmental area.

In contrast to the detailed studies of the relationship between the dopaminergic system and the motor deficit, there are no published studies examining the relationship between central catecholamine metabolism and the cognitive deficit in Parkinson’s disease. Yet there are reports that levodopa therapy can improve both cognitive function and motor function in Parkinson’s disease. A positive correlation has also been reported between the degree of dementia and bradykinesia which in turn has been reported elsewhere to correlate with the deficit in CSF and brain HVA levels. Furthermore there is evidence suggesting it is actually the relative balance of dopaminergic and noradrenergic activity that is important for optimal cognitive function. We therefore thought it of interest to examine the potential relationship of motor and cognitive performance in Parkinson's disease with CSF levels of both HVA and MHPG (the major metabolite of norepinephrine in the CNS) and platelet monoamine oxidase activity (a peripheral source of MAO B, the major intraneuronal degradative enzyme for DA in human striatum).

Method and subjects

The 17 male patients with Parkinson's disease who entered this study were either drug-free and being evaluated for treatment for the first time or had undergone drug washout for at least 2 weeks preparatory to evaluation of new antiparkinsonian agents. Written informed consent was
Table 1 Comparison of unmedicated Parkinson’s disease patients and normal controls with respect to age, central catecholamine metabolites, platelet MAO and cognitive deficit.

<table>
<thead>
<tr>
<th>CSF Metabolites (ng/ml)</th>
<th>Parkinsonian patients</th>
<th>Controls</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>HVA</td>
<td>10.4±2.3 (12)</td>
<td>23±3</td>
<td>3±2 (8)</td>
</tr>
<tr>
<td>MHPG</td>
<td>11.8±1.0 (11)</td>
<td>13±1.6</td>
<td>6±0.8 (16)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Platelet MAO (nmol/mg/hr)</th>
<th>Parkinsonian patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEA</td>
<td>39.8±2.7 (17)</td>
<td>40.2±3.0 (16)</td>
</tr>
<tr>
<td>Vmax</td>
<td>3.3±0.3 (17)</td>
<td>3.3±0.3 (16)</td>
</tr>
<tr>
<td>Km (uM)</td>
<td>3.8±2.6 (17)</td>
<td>4.5±4.2 (16)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MSQ Score</th>
<th>Parkinsonian patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.7±0.4 (12)</td>
<td>0.1±0.2 (8)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>Parkinsonian patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>61.5±1.8 (17)</td>
<td>CSF Controls</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Parkinsonian patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Platelet Controls</td>
<td></td>
</tr>
<tr>
<td></td>
<td>54±2</td>
<td>61±0.8</td>
</tr>
</tbody>
</table>

*p < 0.05. †p < 0.01 2-tail t test contrast with controls.

The 17 Parkinson patients studied had a duration of illness of 13.5±0.4 (SEM) years. The neurochemical findings are summarised in table 1. The mean concentration of HVA in the CSF of the Parkinson's disease group was 45% that of the control group (p < 0.01). There were no apparent differences in the level of CSF MHPG. Because of the possibility that platelet MAO activity may increase in older patients, the platelet MAO control group was age-matched with the Parkinsonian patients. There were no differences in platelet MAO Vmax or Km between the disease group and the control group.

The patients with Parkinson's disease had a moderately severe motor deficit with mean scores of 3.3±1.0 on the scale of Hoehn and Yahr and 852±105 on the New York University Scale. Cognitive function was also impaired. The group as a whole scored below the mean for age and verbal IQ-matched controls on all six subscales of the Guild Memory Scale (see table 2). The degree of deficit was actually very similar across all subscales as can be seen by the percentage differences in the mean scores shown in table 2. These findings could not be attributed to attention deficits or motor function since the digit span score showed the least effect and the designs score, where some degree of motor function is required, was comparable to scores on other subscales of the Guild Memory Scale.
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease

Table 3  Relationship in Parkinson's disease of CSF Catecholamine metabolites and platelet monoamine oxidase kinetics: partial correlation matrix controlling for age

<table>
<thead>
<tr>
<th>CSF metabolites</th>
<th>Platelet MAO kinetics $V_{\text{max}}$</th>
<th>$K_{m}$</th>
<th>Tyramine activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HVA</td>
<td>0.55*</td>
<td>0.04</td>
<td>0.47†</td>
</tr>
<tr>
<td>MHPG</td>
<td>−0.25</td>
<td>0.06</td>
<td>−0.10</td>
</tr>
</tbody>
</table>

*p < 0.05  
†p < 0.10

The motor deficit as measured by the NYU Scale did not correlate with any of the measures of cognitive function. A negative partial correlation controlling for age was found between the motor deficit score on the NYU scale and CSF HVA levels ($r = -0.70$, p < 0.01). No correlation was found with MHPG.

Within the group of neurochemical measures, platelet MAO activity (a peripheral source of MAO B) showed a partial correlation controlling for age with CSF levels of HVA (an MAO B substrate) but not with MHPG (an MAO A substrate) when controlled for age (see table 3). Platelet MAO activity and CSF HVA showed no positive correlation with age in patients with Parkinson's disease, in contrast to positive findings previously reported in both brain and platelet tissue in normal subjects.

The relationships between the measures of cognitive deficit on the Guild Memory Scale and catecholamine metabolites are shown in table 4. Platelet MAO activity showed a positive correlation with the MSQ and 4/6 subscales on the Guild Memory Scale and a trend towards a positive correlation with a fifth subscale (p < 0.10). Thus, higher platelet MAO B activity was associated with better cognitive performance. No significant correlation was seen between HVA and any cognitive measure although the paired associates approached significance (p < 0.10). A negative correlation was found between CSF MHPG levels and the digit span subscale as well as trend towards a negative correlation (p < 0.1) with the paragraphs and paired associates subscales scores. All correlation coefficients with MHPG were negative, regardless of significance. Platelet MAO $V_{\text{max}}$ and MHPG collectively explained 14–39% of the variance in the cognitive subscales of the Guild Memory Scale (see table 4). Similarly, the ratio of HVA to MHPG explained a significant part of the variance for both immediate and delayed recall of the paired associates and the digit span subscales.

Within the cognitive measures carried out on the Parkinson's disease group a strong correlation was found between scores on subscales on the Guild Memory Scale (p < 0.01) supporting the suggestion derived from the relatively equal degree of deficit seen in all the subscales of the Guild Memory Scale that Parkinson's disease did not selectively impair any of the specific cognitive processes measured by the Guild Memory Scale.

Discussion

Our finding of reduced CSF concentrations of HVA in the Parkinson's disease group compared to controls and that the level of HVA correlated significantly with the degree of motor deficit after controlling for age is in agreement with findings in both brain and CSF. We found no differences in CSF MHPG levels between the Parkinson's disease group and controls again confirming a previous report, although there is one postmortem study that reported reduced concentrations of MHPG and NE in Parkinson's disease. As spinal sources of MHPG may obscure a central deficit when measuring CSF MHPG by lumbar puncture, our findings cannot exclude a central deficit of NE.

We also found no differences in platelet MAO enzyme kinetics between the diseased and the control groups which is consistent with the one published study of platelet MAO activity in Parkinson's

Table 4  Relationship of cognitive deficit in Parkinson's disease to CSF catecholamine metabolites and platelet MAO activity: partial correlation matrix controlling for age

| Guild Memory Scale Subtests | HVA     | MHPG    | Ratio HVA MHPG | Platelet MAO kinetics $V_{\text{max}}$ | $K_{m}$ | Tyramine activity | $V_{\text{max}}$ and MHPG $\dagger$
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Paragraphs</td>
<td>−0.30</td>
<td>−0.53†</td>
<td>0.03</td>
<td>−0.51*</td>
<td>0.07</td>
<td>0.33</td>
<td>0.59*</td>
</tr>
<tr>
<td>Paragraph 2†</td>
<td>0.21</td>
<td>−0.23</td>
<td>0.36</td>
<td>0.46†</td>
<td>0.11</td>
<td>0.28</td>
<td>0.52†</td>
</tr>
<tr>
<td>Paired Associates</td>
<td>0.49†</td>
<td>−0.33</td>
<td>0.61*</td>
<td>0.60†</td>
<td>0.24</td>
<td>0.47†</td>
<td>0.60*</td>
</tr>
<tr>
<td>Paired Associates 2</td>
<td>0.31</td>
<td>−0.48†</td>
<td>0.46*</td>
<td>0.76*</td>
<td>0.38</td>
<td>0.60*</td>
<td>0.62*</td>
</tr>
<tr>
<td>Digit Span</td>
<td>0.42</td>
<td>−0.74*</td>
<td>0.61*</td>
<td>0.62*</td>
<td>0.17</td>
<td>0.37</td>
<td>0.53*</td>
</tr>
<tr>
<td>Designs</td>
<td>−0.40</td>
<td>−0.26</td>
<td>0.04</td>
<td>−0.02</td>
<td>−0.75*</td>
<td>0.36</td>
<td>0.37</td>
</tr>
</tbody>
</table>

*p < 0.05  
†p < 0.10

$\dagger$ Delayed recall of paragraph or paired associates

$\ddagger$ Multiple linear regression using $V_{\text{max}}$ and MHPG as independent variables
disease in untreated and levodopa-treated patients. This paper reported no significant differences in platelet MAO activity between controls and the untreated Parkinson's disease group, but because the ratio of MAO activity using the substrates tyramine and m-iodobenzylamine was significantly lower in the Parkinson's disease group, an alteration in the enzyme was postulated. However they did not do enzyme kinetic studies. In our study we did measure MAO enzyme kinetics and found no differences in the Michaelis constant, Km, which suggests that platelet MAO is not altered in Parkinson's disease.

The relationship of platelet MAO to central catecholamine metabolism has only received limited attention. DA is an MAO B substrate in human striatum and platelet MAO is almost entirely type B. We would expect that since MAO is the major intraneuronal degradative enzyme of amines and that genetic factors account for about 70% of the variance in platelet MAO activity, that it may reflect central MAO B activity in contrast to MAO A activity. In fact, consistent with this suggestion, there was a positive correlation between platelet MAO activity and HVA levels but not MHPG levels. Clearly this finding requires further investigation in both diseased and normal control subjects to evaluate to what degree platelet MAO activity can reflect central DA metabolism. Postmortem studies have shown that brain MAO activity can correlate positively with levels of 5-HIAA but detailed studies of correlations between central and peripheral MAO A and B activity and preferred substrates are lacking in human subjects apart from one study that confirmed out findings in normal controls.

Previous reports in other older patient populations have indicated a positive correlation between age and both platelet MAO B activity and CSF levels of HVA. In contrast to these findings in normal subjects, we found no statistically significant correlation between age and either CSF HVA (r = 0.39 p > 0.10) and platelet MAO (r = 0.05 p > 0.10) in Parkinson's disease. These differences could be explained by the effect of the disease upon CSF HVA and the relatively narrow spread of ages in this group which could conceal an age-related rise in platelet MAO activity.

Cognitive testing in our study suggested a mild global deficit that contrasted with the severity of the motor deficit. While animal data suggests certain lesions of the basal ganglia can produce profound deficits in "cognitive function", human diseases of the basal ganglia produce principally motor lesions. Our finding of a mild global cognitive impairment contrasts with some reports in the literature of a more focal cognitive defect. Some of these reports may have failed to allow for motor deficits and since certain visual/spatial tasks may also measure motor functioning, this methodological point may explain why greater deficits have been reported in this area of cognitive function. The differences in both the rate of progression and the underlying neurochemical basis of the cognitive and motor deficits may explain ours and others' failure to find a significant correlation in severity between these two components of Parkinson's disease.

The pattern of correlation after controlling for age between the cognitive test subscores on the Guild Memory Scale and the levels of HVA and MHPG in the CSF was intriguing. We found a statistically significant negative correlation between CSF MHPG and scores on the digit span and a trend for a similar finding (p < 0.10) with the paragraphs and paired associates subscales. Norepinephrine has been shown in animal studies to act as a neuromodulator in facilitating memory functions and our findings in Parkinson's disease suggest a role in cognitive function for NE in man.

We could not rule out an effect for DA in cognitive function in Parkinson's disease because platelet MAO activity and HVA levels showed similar relationships with cognitive deficit that reached statistical significance where higher MAO B activity was associated with higher scores on the MSQ and 5/6 Guild Memory Scale subscores. Consistent with the relationship of MAO B with cognitive function, HVA levels tended to show positive correlations with cognitive function. The ratio of HVA to MHPG correlated significantly with 3/6 Guild subscales and similarly the combination of the two independent variables, platelet MAO Vmax and MHPG contributed significantly to the variance on 4/6 subscales. While these findings suggest a relationship between NE and/or DA and cognitive function, an alternative suggestion is that an imbalance created by DA underfunction and relatively normal NE activity may contribute to the abnormality in cognitive functioning in Parkinson's disease. Clearly a larger series of patients must be studied to see if these data can be confirmed and to investigate these suggested causal relationships.

Our findings suggest that while the motor deficit of Parkinson's disease is related to a deficiency of dopamine in nigrostriatal neurons, certain aspects of cognitive function or dysfunction appear related to both NE and DA or perhaps the relative imbalance that develops between the dopaminergic system and noradrenergic function. These observations emphasise the need for further study of the functional interrelationship between these amnergic systems and cognitive and motor function in order to permit a
better understanding of the neurochemical basis of both the motor and cognitive deficits in Parkinson’s disease.

This work was partly supported by an Andrew W Mellon Teacher-Scientist Award to Dr John Mann. Excellent technical assistance was provided by Ms Joan Kuster, Francesca Iohan and Mr Allaix Philogene. Assistance with data compilation was provided by Ms Maria Collora.

References


33 Marsden CD. The enigma of the basal ganglia and movement. *TINS* November 1980.

34 Mathews CG. Haaland KY. The effect of symptom duration on cognitive and motor performance in parkin-


Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.

J J Mann, M Stanley, R D Kaplan, J Sweeney and A Neophytides

*J Neurol Neurosurg Psychiatry* 1983 46: 905-910
doi: 10.1136/jnnp.46.10.905

Updated information and services can be found at: [http://jnnp.bmj.com/content/46/10/905](http://jnnp.bmj.com/content/46/10/905)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)